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Methods (UPSTREAM) for diagnosis and
management of bladder outlet obstruction
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Abstract
Background: Lower urinary tract symptoms (LUTS) comprise storage symptoms, voiding symptoms and post-voiding
symptoms. Prevalence and severity of LUTS increase with age and the progressive increase in the aged population
group has emphasised the importance to our society of appropriate and effective management of male LUTS.
Identification of causal mechanisms is needed to optimise treatment and uroflowmetry is the simplest non-invasive
test of voiding function. Invasive urodynamics can evaluate storage function and voiding function; however, there is
currently insufficient evidence to support urodynamics becoming part of routine practice in the clinical evaluation of
male LUTS.
Design: A 2-arm trial, set in urology departments of at least 26 National Health Service (NHS) hospitals in the United
Kingdom (UK), randomising men with bothersome LUTS for whom surgeons would consider offering surgery, between
a care pathway based on urodynamic tests with invasive multichannel cystometry and a care pathway based on
non-invasive routine tests. The aim of the trial is to determine whether a care pathway not including invasive
urodynamics is no worse for men in terms of symptom outcome than one in which it is included, at 18 months
after randomisation. This primary clinical outcome will be measured with the International Prostate Symptom
Score (IPSS). We will also establish whether inclusion of invasive urodynamics reduces rates of bladder outlet
surgery as a main secondary outcome.
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Discussion: The general population has an increased life-expectancy and, as men get older, their prostates
enlarge and potentially cause benign prostatic obstruction (BPO) which often requires surgery. Furthermore, voiding
symptoms become increasingly prevalent, some of which may not be due to BPO. Therefore, as the population ages,
more operations will be considered to relieve BPO, some of which may not actually be appropriate. Hence, there is
sustained interest in the diagnostic pathway and this trial could improve the chances of an accurate diagnosis and
reduce overall numbers of surgical interventions for BPO in the NHS. The morbidity, and therapy costs, of testing must
be weighed against the cost saving of surgery reduction.
Trial registration: Controlled-trials.com - ISRCTN56164274 (confirmed registration: 8 April 2014).
Keywords: UPSTREAM, Urodynamics, Prostate, Surgery, Lower urinary tract symptoms, Bladder outlet obstruction,
Benign prostatic obstruction, Randomised controlled trial
Background
The protocol for this study, Urodynamics for Prostate
Surgery Trial; Randomised Evaluation of Assessment
Methods (UPSTREAM) for diagnosis and management
of bladder outlet obstruction (BOO) in men, describes a
major multicentre United Kingdom (UK) trial to estab-
lish whether a care pathway not including invasive uro-
dynamics is no worse than one in which it is included in
men who are considering further treatment where sur-
gery might be an option for BOO. The study is designed
to be as informative as possible, whilst remaining simple
and pragmatic, both for those participating and for those
involved in clinical care. Research nurses and urologists
in each centre will identify and recruit men who are
seeking further treatment, which might include surgery,
for BOO and collect descriptive information, symptom
assessment, flow rates and urinalysis. Those who are eli-
gible will be invited to enter a randomised trial whereby
treatment is based on two different diagnostic pathways;
either routine information only (the ‘non-urodynamic
assessment’ control group) or routine information supple-
mented by urodynamic testing. All men will be followed
up at 6, 12 and 18 months after randomisation.
Lower urinary tract symptoms (LUTS) comprise storage
symptoms (e.g. increased daytime urinary frequency, noc-
turia, urgency, incontinence), voiding symptoms (e.g. slow
stream, intermittency, hesitancy, straining, dribbling) and
post-voiding symptoms (e.g. post-micturition dribble).
Ninety percent of men aged 50 to 80 years suffer from at
least 1 LUTS, which can affect quality of life, occupation
and other activities. Prevalence and severity increase with
age [1] and the progressive increase in the aged population
group has emphasised the importance to our society of
appropriate and effective management of male LUTS.
Identification of causal mechanisms is needed to opti-
mise treatment. In men with voiding LUTS, benign pros-
tate enlargement (BPE) with ageing causes partial BOO, a
situation known as benign prostatic obstruction (BPO).
BPO is a major contributor to LUTS. For such patients,
prostate surgery, such as transurethral resection of the
prostate (TURP), has a good chance of improving LUTS.
However, voiding LUTS can also be caused by bladder
dysfunction: e.g. poor expulsion strength of the bladder
muscle. This is called ‘underactive bladder, or ‘detrusor
underactivity’, as the main bladder muscle anatomically is
called the detrusor. In such men, it is hard to justify pros-
tate surgery if BPO is not present, especially in view of po-
tential adverse effects associated with surgery, such as
blood transfusion requirement, problems of sexual func-
tion, anaesthetic problems or incontinence.
Tests of lower urinary tract function are used in
clinical practice to demonstrate the causes of voiding or
storage problems. Symptom scores are recorded and a
physical examination is performed followed by urinaly-
sis. Uroflowmetry is the simplest non-invasive test of
voiding function. It entails voiding into a recording
device that measures the volume of urine passed and the
rate of urine flow, with an ultrasound scan after voiding
to see how efficiently the bladder has emptied. In
addition, the National Institute for Health and Care
Excellence (NICE) guidance on management of LUTS in
men (CG97) [2], states that invasive urodynamics may
be used when invasive treatment is being considered, or
for equivocal or more complex cases. Invasive urodynam-
ics, which is also called multichannel cystometry, employs
bladder catheterisation for both bladder filling and bladder
pressure measurement, and rectal catheterisation for meas-
urement of abdominal pressure. Concurrent subtraction of
abdominal from bladder pressure by a computer calculates
‘detrusor pressure’, to demonstrate whether bladder con-
traction is occurring. Thus, invasive urodynamics can
evaluate storage function (while the bladder is being filled)
and voiding function (when the man passes urine). Observ-
ing high detrusor pressure associated with only a low urine
flow rate is diagnostic of BOO [3]. Low detrusor pressure
with low flow implies that bladder contractility is impaired
[4]. Without invasive urodynamics, it is uncertain for any
given individual whether the bladder outlet is obstructed,
and whether the bladder is overactive during storage or
underactive during voiding.
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Other diagnostic methods have been evaluated and
reported with up to level-3 evidence. These include:
penile cuff test [5, 6]; urethral reflectography [7]; ultra-
sound measurement of bladder wall thickness and
weight [8]; intravesical prostatic protrusion [9]; resistive
index [10]; and prostatic urethral angle [11]. However,
there is insufficient evidence to warrant any of these
tests becoming standard practice in the clinical evalu-
ation of male LUTS [12].
Health Technology Assessment (HTA) programme
Despite the implicit merit of confirming that BOO is
present before proceeding to surgery to relieve BOO, the
lack of relevant research evidence means that many centres
omit the test from the usual care diagnostic pathway.
Invasive testing is perceived as unpleasant and service
delivery has cost implications. NICE CG97 indicates that
performing an invasive procedure is a balance of the
possible benefits versus the possible risks, and that these
must be explained to the patient during informed consent
for the procedure, and appropriate advice given regarding
potential adverse events.
The HTA addressed this with a commissioning brief
asking the research question: In men considering surgery
for bothersome LUTS, is diagnostic categorisation using
results of invasive multichannel urodynamics worthwhile
from the perspective of the men concerned and the
National Health Service (NHS) compared to not using
multichannel urodynamics?
This research was commissioned by the NIHR-HTA fol-
lowing prioritisation of research questions posed by the
NICE Guideline Development Group for male LUTS,
which indicated that research into the role of invasive
urodynamics would clarify whether it could improve the
outcome of surgery, and whether it should be recom-
mended or not in the future [13]. They considered that
improving the chance of an accurate diagnosis and identi-
fying potential complications was the most important out-
come when considering surgical treatment.
Population
Forty-four thousand new cases of symptomatic BPO are
diagnosed each year. Since BPO is a disease of older
men [14], the number of patients affected is likely to
increase by almost 50 % by the year 2025, in line with
population ageing.
Disease-specific health-related quality of life (HRQOL)
measures are significantly worse in men with higher
symptom severity ratings in population-based studies
[15]. Severe LUTS may require surgical treatment, and
25,000 surgical procedures to relieve BPO are currently
performed each year in the NHS. The most widely-used
approach is TURP using monopolar or bipolar electrodes,
or less commonly laser ablation [16].
Rationale for current study
The NICE clinical guideline group on male LUTS [2] was
unable to identify any methodologically high-quality clin-
ical or economic studies. The literature has been reviewed
by Parsons and colleagues [12] and by various professional
groups in the last decade: most recently the Cochrane
Database Systematic Review, Invasive urodynamic studies
(UDS) for the management of LUTS in men with voiding
dysfunction [17]. None of these reviews was able to iden-
tify high-level evidence on the use of invasive urodynamic
testing in male LUTS.
We reviewed evidence for the diagnostic role of inva-
sive urodynamics in men with LUTS prior to surgery for
BPO. We identified no published randomised controlled
trials (RCTs) with data comparing the standard practice
investigation [18] (urine flow rate measurement (maximum
urinary flow rate (Qmax)) and ultrasound estimate of post-
void residual urine (PVR)), with invasive urodynamics.
One abstract did not have any useable data [19].
Level-3 evidence exists to suggest that patient selec-
tion after invasive urodynamics maximises the outcome
benefits to patients from surgery to relieve BPO, over
and above that given by the standard investigations of
Qmax and PVR. The American Urological Association
(AUA) guidelines recommend that the greater diagnostic
benefits of invasive urodynamics over Qmax/PVR are
discussed with patients prior to the decision for prostate
surgery [20].
From NHS reference costs data, 98,986 UDS were
undertaken on men and women by 131 NHS Trusts in
England in 2011–2012 at a tariff cost of £16.7 million;
no information for use of invasive urodynamics specific-
ally in men is available.
NHS Health Episode Statistics show that approxi-
mately 25,000 TURPs are performed annually. For 100
procedures, the specific equipment and consumables
cost of TURP is approximately £29,000. TURP has a
median hospital stay of 2 days. Significant risks may be
associated: reported mortality is up to 0.25 % [21], and
morbidities can include blood loss, erectile dysfunction
or incontinence, resulting in considerable distress to
patients. Late complications (urethral stricture and blad-
der neck contracture) are reported in up to 9.8 % [21].
Additional NHS costs result from delayed discharge
from hospital, re-admissions and increased primary care
utilisation. These unwanted consequences will increase in
the future, as surgery for BPO increases in line with the
ageing male population, and because most operations are
conducted on older men (in 2010–11, 41 % of TURP oper-
ations were for men of 75 years or more in age). Thus, re-
duction in the number of surgical procedures offers direct
cost savings, reduced resource use and supports the possi-
bility of reconfigurations of surgical services. As the popula-
tion ages, more operations will be considered to relieve
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BPO, some of which may not actually be appropriate. As a
result, there is sustained interest in the diagnostic pathway.
Expressed need
The clinical benefit of invasive urodynamics is in ensur-
ing that surgery to relieve outlet obstruction is used only
in men who actually have BPO. Thus, the NICE clinical
guideline on Male LUTS [2] recommended the following
research question: What is the clinical and cost effective-
ness of multichannel cystometry (invasive urodynamics)
in improving patient-related outcomes in men consider-
ing bladder outlet surgery? They stated that this research
would clarify whether invasive urodynamics could improve
the outcome of surgery, by identifying which patients have
BPO. In addition, level-4 evidence indicates that men are
unlikely to proceed to TURP if they are shown not to have
BPO. Thus, invasive urodynamics has the potential to
reduce overall numbers of surgical interventions for BPO
in the NHS.
Study aims and objectives
In men with bothersome LUTS, we hypothesise that
diagnostic categorisation of BOO using invasive uro-
dynamics improves patient selection for obstruction-
relieving prostate surgery compared to a pathway with
no invasive urodynamic testing. Consequently, this will
make it less likely that the subgroup of men with LUTS
who do not have BOO will elect to undergo surgery,
thereby reducing risk of harm from surgery and poten-
tially worse symptom outcomes.
The aim of the UPSTREAM trial is to determine
whether a care pathway not including invasive uro-
dynamics is no worse for men in terms of symptom out-
come than one in which it is included, at 18 months
after randomisation. This primary clinical outcome will
be measured with the widely-used patient reported out-
come, the IPSS at 18 months postrandomisation. We
will also establish whether inclusion of invasive uro-
dynamics reduces rates of bladder outlet surgery as a
main secondary outcome.
The objectives are to answer the following questions:
▪ Does invasive urodynamics deliver similar or better
symptomatic outcomes for LUTS measured by IPSS
at 18 months after randomisation?
▪ Does invasive urodynamics influence surgical
decision-making, as reflected in differing surgery rates
in the two diagnostic pathways?
▪ What is the cost effectiveness of the 2 diagnostic
pathways, by calculating the incremental cost per
quality-adjusted life-year (QALY) gained at 18 months
post randomisation?
▪ What are the relative harms of invasive urodynamic
tests, and surgical and conservative management?
▪ What subsequent NHS services are required
(including repeat surgery or catheterisation for acute
urinary retention) for men in each arm?
▪ What are the differential effects on other outcomes,
such as quality of life and general health?
A qualitative component has been embedded within
the trial to establish patient-perceived importance of dif-
ferent outcomes, explore patients’ and surgeons’ per-
spectives on experiences of procedures and acceptable
inferiority margins (the minimum difference at which
surgeons would perceive there is a difference between
pathways), and determine reasons for failure resulting in
crossover to alternative treatment. This qualitative work
will also answer the following questions:
▪ What is the acceptability of invasive urodynamic tests
for men, and how satisfied are men with the
diagnostic pathways for LUTS being tested?
▪ How does invasive urodynamic testing impact on
decision-making for both surgeons and men with
bothersome LUTS, assessed using qualitative methods?
Methods
Study design
A two-arm trial randomising men with bothersome
LUTS, for whom surgeons would consider offering
surgery, between a care pathway based on urodynamic
tests with invasive multichannel cystometry (‘urodynam-
ics’ active intervention arm) and a care pathway based on
non-invasive routine tests: i.e. without multichannel
cystometry (‘non-urodynamic assessment’ control arm)
(see Fig. 1, study flow diagram).
Diagnostic pathways and thresholds of testing were in-
formed by a preliminary survey of 30 UK surgeons in 22
departments, which we undertook in 2012. This showed
that the minimum baseline dataset comprises IPSS, Qmax
with post-void bladder ultrasound scan and urinalysis.
Setting
Urology departments of at least 26 NHS Hospitals in
the UK. These currently include: Southmead Hospital,
Bristol; Freeman Hospital, Newcastle upon Tyne; Royal
Devon and Exeter Hospital, Exeter; Musgrove Park Hos-
pital, Taunton; Southport and Formby District General
Hospital, Southport; Kingston Hospital, Kingston upon
Thames; Royal Hallamshire Hospital, Sheffield; Epsom
General Hospital, Epsom; Queen Elizabeth Hospital,
Birmingham; Kent and Canterbury Hospital, East Kent
and Canterbury; Salisbury District General Hospital,
Salisbury; Lister Hospital, Stevenage; Churchill Hos-
pital, Oxford; The James Cook University Hospital,
Middlesbrough; The Queen Elizabeth Hospital, King’s
Lynn; Royal Free Hospital, London; Royal Liverpool
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University, and Broadgreen, Hospitals; Torbay Hospital,
Torbay; Southampton General Hospital, Southampton;
Kettering General Hospital, Kettering; Charing Cross
Hospital, London; Royal Berkshire Hospital, Reading;
Derriford Hospital, Plymouth; West Cumberland Hospital,
Cumbria; Sunderland Royal Hospitals, Sunderland; and
St George’s Hospital, London.
Additional sites will be identified if required.
Participants
Men with bothersome LUTS and suspected BOO for
whom surgeons would potentially offer surgery.
Inclusion criteria
▪ Men seeking further treatment for their bothersome
LUTS which may include surgery
Fig. 1 Study flow diagram
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Exclusion criteria
▪ Unable to pass urine without a catheter (urinary
retention) (excluding clean intermittent self-
catheterisation (CISC) after void to empty)*
▪ Relevant neurological disease, such as a stroke,
multiple sclerosis, Parkinson’s disease, or spina bifida
(diabetes mellitus is not an exclusion criterion unless
it is causing diabetic neuropathy)
▪ Undergoing active treatment, or on active
surveillance, for prostate or bladder cancer (including
low-grade/stage transitional cell cancer)
▪ Previous prostate surgery
▪ Not medically fit for surgery, or unable to complete
outcome assessments
▪ Men who do not consent to be randomised and/or
are not willing or able to comply with essential study
procedures
*CISC is acceptable in situations where it is used occa-
sionally to drain a post- void residue. However, entire
reliance on CISC for all bladder emptying, or use of
CISC to dilate a urethral stricture is not acceptable.
Planned interventions
Baseline clinical assessment for all men
Following consent and randomisation, all men will
undergo assessment as set out in the NICE clinical
guideline on Male LUTS [13]:
▪ Assessment of general medical history to identify
possible causes of LUTS, and associated comorbidities.
Review of current medication
▪ Physical examination guided by urological symptoms
and other medical conditions, an examination of the
abdomen and external genitalia, and a digital rectal
examination (DRE)
▪ Urinalysis (dipstick, or microscopy and culture)
▪ Urinary frequency volume chart (bladder diary)
▪ Measurement of urinary flow rate, with post-void
residual volume measurement by ultrasound. (Note: a
urinary flow rate test, recorded up to 6 months prior
to date of informed consent, is acceptable to avoid
unnecessary repeat for the patient)
Discretionary tests
As this is a pragmatic trial, additional tests may be
undertaken according to the usual practice of the
research sites. For example, the following tests may be
undertaken in line with the NICE clinical guideline on
Male LUTS [13]:
▪ Information, advice and time to decide if they wish to
have prostate specific antigen (PSA) testing if their
LUTS are suggestive of BPO, or their prostate feels
abnormal on DRE, or they are concerned about
prostate cancer
▪ Cystoscopy only when clinically indicated: e.g.,
recurrent infection, sterile pyuria, haematuria,
profound symptoms, or pain
▪ Imaging of the upper urinary tract when clinically
indicated: e.g., chronic retention, haematuria,
recurrent infection, sterile pyuria, or pain
Interventions for randomised men
‘Non-urodynamic assessment’ control arm (usual care)
Men will have clinical treatment based on the baseline
clinical assessment described above.
Intervention arm (usual care plus urodynamics assessment)
Men will undergo the routine baseline clinical assess-
ments set out above. In addition, they will undergo
invasive urodynamics, in which catheters are used to
measure bladder and abdominal pressures, during blad-
der filling and passing urine. Invasive urodynamics is
used to calculate voiding parameters (BOO index, con-
tractility) and assess urine storage (detrusor overactivity,
bladder capacity). Hence, it should distinguish men with
BOO, who should benefit from surgery to relieve ob-
struction, from men with reduced bladder contractility,
who are unlikely to benefit from surgery, or those with-
out obstruction with storage disorders or normal urody-
namic findings.
Method of urodynamic testing
Quality of urodynamic testing will be according to Inter-
national Continence Society Good Urodynamic Practice
requirements [22]. The following technical aspects of
invasive urodynamic testing will be reviewed for each
centre (mandatory):
▪ Appropriate equipment maintenance and calibration
testing consistent with manufacturer instructions
according to the unit log
▪ Measurement of bladder and abdominal pressure,
including resting pressures within expected limits
▪ Concurrent computing of detrusor pressure
▪ Extrinsic filling at ‘physiological rates’
▪ Checks of pressure transmission (e.g. subtraction of
cough impulse) during filling and after voiding
▪ Trace labeling for later re-interpretation; e.g. reporting
of key events (e.g. detrusor overactivity, permission to
void), bladder sensations and timing of ‘provocation
tests’ and ‘permission to void’
▪ Correction for artefacts during computation of BOO
and bladder contractility indices
▪ Correspondence of written report to symptoms and
specific features of the original traces
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Surgical management
After diagnostic testing with (intervention arm) or with-
out (control arm) urodynamics, patients will see their
surgeon to decide on whether to proceed to surgical
treatment. The treatment decision is between the urolo-
gist and the patient and there are no treatment ‘require-
ments’ imposed by the UPSTREAM study. We aim to
capture urologist and patient opinions about treatment
decisions in the relevant case report form(s) (CRF). As a
pragmatic trial, standard practice for the centres will be
followed, relating to type of surgery (providing it is a
NICE-approved surgical procedure, e.g. monopolar or
bipolar TURP, or laser), whether to stay on LUTS medi-
cations, antibiotic prophylaxis and other factors. Type of
surgery will be recorded. All conservative and surgical
management plans and actual treatment received will be
documented. As this is a pragmatic study, surgeons may
feel it necessary in some cases to conduct additional
tests outside of the participant’s allocated intervention
group. Centres are asked to record, in the baseline CRF,
whether the participant received the diagnostic assess-
ments that they were randomly allocated to, and provide
reason(s) if assessment was different to that allocated.
As we are recording assessments received versus as-
sessment allocation in trial document, such a deviation
would not require additional ‘Protocol Noncompliance’
reporting.
All other Good Clinical Practice (GCP) and/or proto-
col deviations should be recorded on the ‘GCP/Protocol
Noncompliance Report Form’ (provided in the Site File)
and forwarded to the Trial Manager who will notify the
Chief Investigator (CI) and Trial Sponsor.
Allocation to trial groups
All eligible and willing men will be randomly allocated
to receive one of two assessment pathways, as outlined
above; that is either a) usual care (non-urodynamics,
control); or b) usual care plus urodynamics assessment
(intervention).
All men who enter the study will be logged with the
central trial office and given a unique six-digit study
(participant) identification number. Randomisation will
utilise the existing proven remote automated computer
randomisation application at the study administrative
centre in the Bristol Randomised Trial Centre (BRTC, a
fully registered UK CRN clinical trials unit) in the
University of Bristol. The randomisation application will
be available to participating centres, both as a telephone-
based interactive voice response (IVR) system and as an
Internet-based service, for them to complete the random-
isation procedure themselves, on site.
Further details of ‘Identification, Recruitment and
Consent’ are outlined below (page 10).
Study outcome measures
The measures have been selected according to the speci-
fications of the HTA commissioning brief.
Primary outcome measure
▪ Primary clinical outcome: difference in lower urinary
tract symptom (LUTS) between the 2 arms at 18
months (post randomisation), measured with the
IPSS. IPSS is validated [23], well-known and widely
used in the NHS.
Secondary outcome measures
▪ Surgery rate (the relative proportion of men in each
group having surgery up to 18 months after
randomisation)
▪ Cost-effectiveness analyses from the perspectives of
the NHS, personal social services and patients.
Subsequent need for surgery (related to their LUTS)
during any stage of the trial will be recorded
▪ Adverse events of testing and treatment (e.g. infection,
urinary retention)
▪ Measures from the International Consultation on
Incontinence Questionnaires (ICIQ) [24] will be used
alongside the IPSS, giving sensitive and comprehensive
assessment of LUTS severity/bother, sexual
function, quality of life and satisfaction with
urodynamic testing. The following will be measured
at 6, 12 and 18 months:
▪ IPSS
▪ ICIQ Male LUTS (ICIQ-MLUTS)
▪ ICIQ sexual function in Male LUTS (ICIQ-
MLUTS-sex)
▪ ICIQ urodynamics satisfaction (ICIQ-UDS-S) will be
administered at a single time point after urodynamic
testing for the interventional arm
▪ Qmax at 18 months. In men undergoing surgery in
both arms, an additional Qmax measure at 4 months
after operation will be used as a quality measure for
surgery
▪ The EuroQol Group’s 5 dimension health status
questionnaire (EQ-5D-5 L) will be used to provide the
quality of life weights used to calculate QALYs
▪ Qualitative interviewing will explore user acceptability
and influences on decisions made by the participating
men and the surgeons
In addition, all men will be invited to consent to long-
term follow-up, including use of computerised NHS re-
cords, Hospital Episodes Statistics (HES) data and other
routine data sources.
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Participant entry
Identification, recruitment and informed consent
All eligible men referred with voiding LUTS will be
identified by the consultant, dedicated research nurse, or
designated team member at time of receipt of referral
letter or during patients’ clinical appointments. Hospital
staff should complete trial-specific screening logs for all
potentially eligible men and provide confirmation of the
patient’s outcome for the study; this will be one of three:
1) patient confirmed as ineligible; 2) patient was eligible
but declined to take part; and 3) patient was eligible and
consented to take part. These will be reviewed by the
UPSTREAM Office Team (BRTC) on a monthly basis.
Due to variation in patient pathways in each hospital,
these arrangements should be individualised according
to local circumstances in each site. Those patients iden-
tified from referral letters will be sent a Patient Informa-
tion Sheet (PIS), Assessment Information Sheet (AIS)
and covering letter. Alternatively, the research nurse will
describe the study to the patients at their clinical
appointment and, if interest is expressed, provide further
details of the study by means of the PIS and AIS. An
approved study-specific poster can also be displayed in
suitable clinic rooms, which provides the contact details
of trial-related staff that interested men can contact for
further information.
If the patient agrees to the study, they will be given a
chance to ask questions and should ideally have at least
24 hours to think about taking part before being con-
sented and randomised. Written informed consent will
be obtained from all patients who agree to take part in
the study. The PIS and the consent form will refer to the
possibility of long-term follow-up and being contacted
about other research if the man is willing. If the patient
is happy to take part in the study without having been
given PIS and study details over the previous 24 hours,
and requests to provide written consent and complete
baseline questionnaires at that time (i.e. to avoid having
to return to the hospital for an additional appointment)
this is possible. In such cases we suggest that the
research centre completes written consent and baseline
questionnaires, there and then, but does not randomise
the patient until at least 24 hours have passed. After at
least 24 hours, the centre should contact the patient by
telephone to confirm whether they are still willing to
proceed with the study, and if so, the centre can proceed
with randomisation and inform the patient of his inter-
vention allocation via the telephone. If the patient has
changed his mind, however, and no longer wishes to be
randomised, the research centre should complete the
‘UPSTREAM Change of Permissions/Withdrawal Form’
accordingly, and follow essential reporting procedures
specified on the form. For clarity, a copy of the consent
form and completed Change of Permissions/Withdrawal
Form should be kept at site, as well as forwarded to the
UPSTREAM Office Team for records. All other data col-
lected for such a patient, however, such as baseline ques-
tionnaires, should be suitably discarded by the research
site; the trial has no need to retain this information as
the patient has decided not to enrol (be randomised)
into the trial. For men who are randomised, the research
centre should also record that the patient opted for this
consent and randomisation approach in their medical
notes, and in the UPSTREAM Baseline CRF (Comments
section). This alternative consent and randomisation
process helps the patient to avoid returning the hospital
simply for the purpose of the trial.
Men who are not willing to be randomised, but who
would otherwise be eligible, will be asked to consent to
being contacted for qualitative research to explore rea-
sons for non-participation.
All men who enter the study will be logged with the
central trial office and given a unique six-digit study
(participant) identification number, and randomised.
Hospital staff will complete and send a study ap-
proved letter to the participant’s General Practitioner
(GP) informing them that their patient has entered
into the trial.
Hospital staff will be informed about the study by the
Principal Investigator (PI) and the research nurse, so
that they can answer queries from participants and their
relatives.
Withdrawal criteria
Participants will remain in the trial unless they choose to
withdraw or if they are unable to continue for a clinical
reason. If a participant withdraws consent, further partici-
pant questionnaires will not be collected. However, per-
mission will be sought for the research team to continue
to collect outcome data from their health care records.
Participants are informed in the PIS that they have the
right to withdraw all personal data held by the study.
Study specific procedures for a participant’s change of per-
missions, or withdrawal, are outlined in the relevant trial
working guidelines.
Randomisation, blinding and prevention of bias
Randomisation
All men who enter the trial will be logged with the central
study office and given a unique, six-digit study (partici-
pant) identification number. Randomisation will utilise the
existing proven remote automated computer randomisa-
tion application at the study administrative centre in the
BRTC. Participants will be randomly allocated to treat-
ment arms using an automated web/telephone randomisa-
tion system provided by the BRTC. Randomisation will be
stratified by centre.
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Blinding
Blinding in the urodynamic unit is not possible nor
appropriate in this pragmatic trial, given that men are
only catheterised in the invasive group, hence group
allocation cannot be concealed from the man or the
staff. We do not feel it is necessary or ethical to perform
sham catheterisation to conceal the nature of testing.
Furthermore, knowledge of the results of urodynamic
testing underpins the urologist’s ability to make a man-
agement decision, in conjunction with his patient, so
neither the man nor his urologist can be blinded to the
intervention or its findings. However, outcome assess-
ment is largely by participant self-completed question-
naire, so avoiding interviewer bias.
Methods to protect against bias
Urodynamic techniques
We will centrally monitor deviations from agreed proto-
cols and review > 10 % traces from each research centre.
All investigators are already experienced urodynamics
investigators, or work with an experienced urodynamics
unit meeting the national minimum standards.
Standardisation of surgical techniques
All investigators are already experienced prostate (TURP)
surgeons. The research nurses and the surgeons will
complete a Peri-Operative CRF at the time of surgery, in-
cluding any intra-operative difficulties or complications.
As this is a pragmatic trial, surgical procedure and post-
operative care will be according to local centre practice.
Loss to follow-up (attrition bias)
Loss to follow-up in our previous trial of conservative
treatment for men with urinary incontinence after pros-
tate surgery [25] was 5 to 10 % at 1 year. However, a
more conservative estimate of just over 20 % loss to
follow-up has been used in the sample size calculations.
We will take very active measures to minimise loss of
men from the study in line with Research Ethics
Committee approval, such as reminder letters, phoning/
texting/ emailing the men, obtaining back-up ‘best con-
tact’ addresses, using non-contingent retention incen-
tives [26], and checks with their GPs [27]. In addition,
we will obtain consent from the men to enable us to
access centrally-held NHS data; e.g., via the NHS Stra-
tegic Tracing Service in England and Wales to find new
addresses, and electronic data linkage which records any
in-patient episodes and outpatient visits.
Other sources of bias (detection bias)
Where feasible, research staff will be blinded to allocation
while conducting data collection for outcomes, perform-
ing data entry and analysis, and by using study numbers
only to identify men, questionnaires and diaries. Men will
be asked not to reveal information about their diagnostic
evaluation and treatment. Staff will be asked in the 18-
month CRF to record whether or not they knew which
group the man had been allocated to, and hence which
diagnostic tests were performed before undertaking out-
come assessments. All men will be actively followed up,
with analysis based on the intention-to-treat principle. All
analyses will be clearly pre-defined to avoid bias.
Adverse events
Adverse event (AE)
An AE includes any untoward medical occurrence in a
study participant, including abnormal laboratory results,
symptoms or a disease that does not necessarily have a
causal relationship with procedures required by the proto-
col. In all instances it will be up to the physicians respon-
sible for the participants’ care to determine whether the
person’s change in health is related to the trial.
AEs are not:
▪ continuous and persistent disease or symptom, present
before the trial, which fails to progress
▪ signs or symptoms of the disease being studied; or
▪ treatment failure
For the UPSTREAM study, pre-planned hospitalisa-
tion or elective procedures: e.g. for pre-existing condi-
tions which have not worsened, does not constitute an
AE. However, any hospitalisation of a pre-existing condi-
tion resulting from worsening, or elective procedures
booked after the patient has signed the consent form
would constitute an AE.
Serious adverse event (SAE)
An adverse event is defined as ‘serious’ (SAE) if it:
▪ results in death of the participant
▪ is life-threatening: the term ‘life-threatening’ refers to
an event in which the participant was at risk of death
at the time of the event; it does not refer to an event
which hypothetically might have caused death if it
were more severe
▪ requires hospitalisation, or prolongation of existing
inpatient hospitalisation
▪ results in persistent/significant disability/incapacity
▪ is otherwise considered medically significant by the
investigator*
*Important AEs that are not immediately life-threatening
or do not result in death or hospitalisation but may jeop-
ardise the subject or may require intervention to
prevent one of the other outcomes listed in the defini-
tions above, may also be considered serious. Medical
Bailey et al. Trials  (2015) 16:567 Page 9 of 20
judgment will be exercised in deciding whether an AE
is serious in other situations.
Expected, related adverse events
Within UPSTREAM, an AE is defined as ‘related’ if it
occurs as a result of a procedure required by the protocol,
whether or not this procedure is the specific intervention
under investigation and whether or not it would have been
administered outside the study as normal care.
The following events are expected, related AEs during/
after any diagnostic procedures:
▪ urinary tract infection
▪ bacteriuria
▪ haematuria
▪ urinary retention
▪ discomfort
▪ dysuria
▪ urethral trauma
The list below itemises the expected, related AEs sum-
marised from the literature for prostate surgery:
▪ excess blood loss (> 500 ml)
▪ blood transfusion
▪ urethral injury
▪ bladder injury
▪ bowel injury
▪ injury to blood vessels or nerves
▪ anaesthetic complications
▪ thrombosis/deep vein thrombosis/pulmonary embolism
▪ prolongation of post-operative catheterisation
▪ recatheterisation
▪ urinary tract infection
▪ other infection (sepsis, septicaemia, abscess)
▪ new urinary tract symptoms
▪ constipation
▪ discomfort/pain
▪ new sexual problems
▪ death
Complication rates will be recorded and classified
using the internationally accepted Clavien-Dindo classifi-
cation in trial CRFs [28].
Reporting procedures for adverse events
Within UPSTREAM, all adverse (serious and non-serious)
events should be recorded on the ‘UPSTREAM Adverse/
Serious Adverse Events’ form, whether originally notified
on a CRF, participant questionnaires or by other means. In
addition, all deaths with any cause (related to the trial or
otherwise) should also be recorded on the ‘UPSTREAM
Adverse/Serious Events’ form.
All AEs should be reported to the UPSTREAM Study
Office Team; depending on the nature of the event the
reporting procedures below should be followed.
Non-serious adverse events
All AEs, whether expected or not, should be recorded
using the ‘UPSTREAM Adverse/Serious Adverse Events’
form. The UPSTREAM online database should also be
updated accordingly by the local research centre at the
earliest opportunity. A copy of the completed form
should be kept in the Site File and in the patient’s notes.
Serious adverse events (SAEs)
Local PI or Research Nurse: all SAEs including deaths
from any cause (related or otherwise) should be recorded
on the ‘UPSTREAM Adverse/Serious Adverse Events’
form, whether originally notified on a CRF, participant
questionnaires or by other means. The completed form
should then be forwarded to the Trial Manager within 24
hours of learning of a SAE, or within 24 hours in the event
of death. Detailed reporting procedures for SAEs are
found in trial specific working guidelines.
Chief Investigator (CI)/or Trial Manager:
▪ The Trial Manager will inform the CI of all SAEs. If,
in the opinion of the local PI and the CI, the event is
confirmed as being serious and related and unexpected,
the CI or Trial Manager will notify the sponsor within
15 days (24 hours in the event of death) of receiving
the AE notification. The sponsor will provide an
assessment of the SAE
▪ The CI (or Trial Manager) will report any related and
unexpected SAEs to the main Research Ethics
Committee and the Data Monitoring Committee
(DMC) within 15 days of the CI becoming aware of it
▪ All related SAEs will be summarised and reported to
the Ethics Committee, the Funder, the DMC and the
Trial Steering Committee (TSC) in their regular
progress reports
Assessment and follow-up
Clinical outcomes
Clinical outcomes will be assessed by participant-
completed questionnaires at baseline, 6 months (postal
(or online or by telephone if required)), 12 months
(postal (or online or by telephone if required)) and 18
months post randomisation (clinic appointment). Free
flow rate testing (maximum flow rate, voided volume
(VV), post-void residual) will be used at baseline and 18
months; an additional measurement of flow rate in men
undergoing surgery in both groups at 4 months after
surgery (± 1 month) will provide objective assessment of
effective relief of BOO. The components and timing of
follow-up measures are shown in Table 1.
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Where possible, telephone interviews will be conducted
with men who withdrew or declined randomisation.
Steps will be taken to minimise loss to follow-up,
including reminder letters and telephone calls. In particu-
lar, the primary outcome measure (IPSS at 18-months
post randomisation) could be collected via the telephone
if necessary.
Economic data collection
Resources used in relation to the management of
bothersome LUTS will be measured from randomisation
to 18-month follow-up. The CRFs will be used to meas-
ure: the initial hospital resource use during the diagnos-
tic phase of the trial; the perioperative stay for those
men who subsequently undergo surgery and, with the
exception of this surgery, any in-patient stays, out-
patient visits and procedures occurring at the treating
hospitals, where the study has research governance
approval, from the end of the diagnostic phase until the
end of the 18 month follow-up period for any man who
has had any non-routine follow-up hospital care, as
identified at the 18-month clinic follow-up. The CRFs
will be designed so that the resource use collected can
be costed using NHS tariffs. At baseline, 6 and 12
months follow-up the men will be given a study
designed Resource Use Log (RUL) to be used as an aide
memoire in which to record prospectively NHS hospital
and community-based health care use, medications,
social service resource use, time off work and any other
expenses resulting from their treatment. The baseline
RUL (0–6 months) will be given to the patients at the
baseline assessment clinic; all subsequent RULs will be
posted by the UPSTREAM Office Team. These logs will
reflect the design of the 6, 12 and 18-month resource
use questionnaires respectively. At the baseline and 18-
month follow-up clinic appointments, resource use
questionnaires will be interviewer-administered if time
permits, otherwise the questionnaires will be given to
the men at the clinics for them to complete in their own
time, and return them by post if necessary. At 6-month
and 12-month follow-up, self-completed resource use
questionnaires will be posted to the men for them to
complete, using the information from the RUL.
The EQ-5D-5 L will be included within the question-
naires given to all men at baseline, 6, 12 and 18 months
follow-up.
Medical record abstraction
At 18 months follow-up, in-patient stays, out-patient
visits and procedures relating to the man’s urinary
symptoms, identified though the 18-month resource
use questionnaire occurring in the treating hospitals,
where the study has research governance approval, will
be abstracted from the patients’ medical records. In
such a way that the resource use collected can be
costed using NHS tariffs.
Qualitative data collection
The aim of the study is to understand patients’ and
health care professionals’ views and experiences of
invasive urodynamic testing for male BOO and BOO
surgery.
Table 1 Measurement outcomes table: components/timing
Baseline Urodynamics Peri-operative 4 mths post surgery 6 mths 12 mths 18 mths
All pts UDS pts Surgery pts Surgery pts All All All
CRFs ● ● ● ● ●
IPSS ● ○ ○ ●
ICIQ-MLUTS ● ○ ○ ●
ICIQ-MLUTSsex ● ○ ○ ●
ICIQ-UDS-S ●
Flow rate/PVR ● ● ●
EQ-5D-5 L ● ○ ○ ●
Resource use questionnaire ● ○ ○ ●
Bladder diary ● ●
Case note review ⋄
Qualitative interview*
(selected patients)
1 week after treatment decision At end of treatment
Qualitative interview (staff) ●
● Clinic/Hospital; ○ Postal; ⋄ Hospital sources; *at home or by telephone
CRF case report form, EQ-5D-5 L EuroQol Group’s 5 dimension health status questionnaire, ICIQ-MLUTS International Consultation on Incontinence Questionnaires
Male lower urinary tract infections, ICIQ-MLUTSsex International Consultation on Incontinence Questionnaires sexual function in Male LUTS, ICIQ-UDS-S
International Consultation on Incontinence Questionnaires urodynamic satisfaction; IPSS International Prostate Symptom Score, mths months, pts patients, PVR
post-void residue, UDS urodynamic studies
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Objectives:
▪ To explore through qualitative methods patients’
views, experiences and beliefs about LUTS
▪ To examine patients’ understanding and knowledge of
testing for BOO and treatment expectations
▪ To understand patients’ and health care professionals’
experiences of the trial, including their experience,
opinions, acceptability and feasibility of invasive
urodynamic testing/non-urodynamic assessment
▪ To investigate patients’ and health care professionals’
decision-making regarding surgery for male BOO
▪ To use qualitative methods to understand barriers
and facilitators to invasive urodynamic testing
▪ To explore the information and support needs of
patients and health care professionals in relation to
invasive urodynamic testing and BOO surgery
▪ To investigate patients’ and health care professionals’
experiences, attitudes and opinions regarding male
BOO surgery and recovery
Overview
In order to examine the views and experiences of inva-
sive urodynamic testing for male BOO we will conduct
in-depth semi-structured qualitative interviews with pa-
tients and health care professionals involved in their
care. Qualitative findings will help to illuminate the per-
ceived effectiveness and acceptability of invasive urody-
namic testing for male BOO, its impact on clinical
decision-making and explore any barriers to their uptake
outside of the trial.
Qualitative methods have been chosen as the most ap-
propriate means to achieving a deep understanding of
beliefs and perceptions of key medical events [29, 30].
Interviews allow for the exploration of complex and
sensitive issues, allowing participants to engage in a
dialogue in their own language and drawing on their
life experiences to explore the issues which are import-
ant to them.
Previous studies have successfully utilised qualitative
methods to investigate patients’ views, experiences and
health beliefs about LUTS [31–34], triggers and barriers
to help seeking [35] perspectives on treatment out-
comes [36]. However, to our knowledge to date no
studies have examined patients’ and health care profes-
sionals’ views and experiences regarding invasive urody-
namic testing for BOO. We are combining qualitative
methods and controlled trial methods as has long been
advocated [37].
Study design
In-depth interviews [38] will be conducted with trial par-
ticipants (from all arms of the trial). Purposive sampling
will ensure that adequate numbers of interviews will be
conducted with men from each of the possible rando-
mised groups according to treatment allocation. Firstly,
participants will be interviewed 1 week after a decision
has been made regarding treatment. These interviews
will consider and compare their views and experiences
of the trial, explore participants’ experiences of LUTS,
understanding and knowledge of BOO, views and
experiences of invasive urodynamic testing, decision-
making regarding surgery and information and sup-
port needs.
A second interview will be conducted with a second
group of participants 18 months after randomisation
(after treatment has been completed) to additionally ex-
plore views and experiences of treatment and recovery.
Telephone interviews will be conducted with a sample
of men who withdrew from the trial. In addition, tele-
phone interviews will be conducted with those who
declined to be randomised in the trial. Health care pro-
fessionals will also be interviewed at the end of the trial
to gather data on their views and experiences of as-
sessment with and without urodynamics, information
and support needs and their attitudes to its future
implementation.
Health care professionals (e.g. urologists, urodynamics
technicians, nurses, etc.) involved in the trial will be pur-
posively sampled in relation to (i) the trial site and (ii)
length of time since qualification.
The sample sizes will be determined by the need to
achieve data saturation, such that no new themes are
emerging from the data by the end of data collection
[39]. Interviews will be analysed in batches, and sam-
pling will continue until no new themes are emerging
from the interviews. This is likely to include up to 30
health care professional and 45 face-to-face trial patient
interviews and 20 telephone interviews with those that
declined trial participation or withdrew from the trial.
The sampling frame is shown in Table 2.
Interview conduct
A flexible topic guide will be used in order to assist
questioning during in-depth individual interviews. The
topic guide will be devised to ensure that the primary is-
sues are covered across all interviews, but do not dictate
data collection. The topic guide will incorporate consid-
erable flexibility to enable participants to introduce new
issues unanticipated by the researchers. Topic guides
will be modified as necessary throughout the course of
the study to reflect findings as they emerge. The re-
searcher will use open-ended questioning techniques to
elicit participants’ own experiences and views of key
events and participants will be asked to provide exam-
ples. Interviews will be recorded, transcribed and anon-
ymised to protect confidentiality.
Bailey et al. Trials  (2015) 16:567 Page 12 of 20
Data analysis
Interview transcripts will be checked for accuracy and
then imported into NVivo qualitative data analysis soft-
ware (QSR International, Daresbury, UK) which aids the
management and indexing of qualitative data. Analysis
will inform further data collection: for instance, analytic
insights from data gathered in earlier interviews will help
identify any changes that need to be made to the topic
guide during later interviews.
Thematic analysis [40], utilising a data-driven induct-
ive approach [41], will be used to scrutinise the data in
order to identify and analyse patterns and themes of par-
ticular salience for participants and across the dataset
using constant comparison techniques [42, 43].
Firstly, the transcripts will be read several times, to
gain familiarisation with the data and initial ideas
noted. The transcripts will then be examined on a line-
by-line basis with inductive codes being assigned to
the segments of the data that provide insight into the
participants’ views and understanding of their experi-
ences. An initial coding frame will be developed and
new data will be compared initially to previous data,
and then to the properties of emerging categories that
contain the main themes. The process of constant
comparison will allow for the generation of new
themes, re-classify themes and incorporating themes
within other themes [42, 43] and the coding frame will
be modified, if needed, as analysis develops. The data
will be scrutinised for negative cases and reasons for
the deviance will be explored by comparison with the
whole dataset.
Transcripts from the patients’ and health care pro-
fessionals’ interviews will be analysed separately, with
coding frames being developed for each separate phase
of the research. A subset of transcripts will be inde-
pendently double-coded by other members of the re-
search team and compared; any discrepancies will be
discussed within the research team and resolved in
order to achieve a coding consensus and to ensure ro-
bust analysis.
Data management and security – overall trial
Data collection and transportation
All data held in Bristol will conform to the University
of Bristol Data Security Policy and in Compliance with
the Data Protection Act 1998. Data collected on the
paper CRFs at study centres or as questionnaires from
participants will be identifiable only by participant
study number. Information capable of identifying indi-
viduals and the nature of treatment received will be
held in the database with passwords restricted to UP-
STREAM study staff.
Audio recordings of qualitative data made during the
interviews will only refer to the participant by their
study number.
Retention of data
Patient identification codes will be held by BRTC for 15
yearsand all other data sources will be stored for 10
years after the close of the study. Personal data (e.g.
name and address, or any data from which a participant
might be identified) will be withdrawn from the study if
this is requested by a participant.
Access to the data
The Senior IT Manager (in collaboration with the CI)
will manage access rights to the data set. Prospective
new users must demonstrate compliance with legal, data
protection and ethical guidelines before any data are re-
leased. We anticipate that anonymised trial data will be
shared with other researchers to enable international
prospective meta-analyses.
IT security
All IT systems supported and maintained by the University
of Bristol Information Services will have infrastructure
including server and server-based applications and desktop
system maintenance. All NHS IT systems will be similarly
supported. Data is stored centrally on robust data systems
with file versioning and recovery and mirroring on a
Table 2 Sampling frame
Arm Urodynamic testing Non-invasive testing Total
Treatment Surgery Conservative Surgery Conservative
IPSS/ICIQ-MLUTS storage subscales High Low High Low High Low High Low
Pre treatment (after treatment decision) 4 4 4 4 3 3 3 3 28
Post treatment 4 4 4 4 16
Total trial interviews (to include a mix of older/younger, randomised groups receiving surgery or conservative treatment and location
(weighted towards Bristol)
44
Telephone interviews with decliners and withdrawals (approximately 20 minutes each) 20
Grand total 64
ICIQ-MLUTS International Consultation on Incontinence Questionnaires Male lower urinary tract infections, IPSS International Prostate Symptom Score
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second site. The BRTC Randomisation system infrastruc-
ture is also maintained by University Information Services.
Auditing and inspection
The study may be subject to inspection and audit by
North Bristol NHS Trust (NBT) under their remit as
sponsor, and other regulatory bodies, to ensure adherence
to GCP and the NHS Research Governance Framework
for Health and Social Care (2nd edition).
Statistics and data analysis
Sample size determination
We decided that the important consideration is that
the group of men randomised to having urodynamics
should have clinical outcomes which are not inferior
(rather than equivalent) to those who are randomised
to management without urodynamics. This is because
the likely reduction in surgery rates in the former
group due to more accurate diagnosis should not
disadvantage them in terms of clinical improvement.
We therefore calculated our sample size based on
both the primary outcome and surgery rates: non-
inferiority of symptoms at 18 months after random-
isation; and a reduction in surgery rates in the
intervention arm.
In Bristol, audit data for 5670 men presenting with
LUTS suggestive of poor or obstructed urine flow
show that 73 % to 83 % would have surgery. If an
invasive urodynamics test was conducted on the same
men, the data indicate that surgery would only be
carried out in 60 %, based on the prevalence of
impaired bladder contractility contraindicating sur-
gery. Using the more conservative difference we ex-
pect the intervention to reduce surgery from 73 % in
non-urodynamic assessment to 60 % in the interven-
tion arm.
Symptom scores will potentially improve for those
men in both arms who undergo appropriate surgery.
Symptomatic outcome of surgery is confounded by a
number of factors for which we cannot control. These
include:
▪ Long-standing BPO might impair bladder contractility,
reducing the symptom benefit of surgery
▪ BPO-relieving surgery increases the calibre of the
outlet channel regardless of whether BPO is present,
and this might improve urinary stream in men who
technically did not have BPO
▪ A ‘placebo effect’ is known to arise both from clinical
contact and from the surgical procedure
▪ Whilst voiding LUTS (obstruction) typically improves
after surgery, this advantage will be offset in some
men due to deterioration in storage LUTS
(e.g. incontinence, overactive bladder)
We therefore anticipate the overall IPSS at 18 months
in both arms might be similar despite group differences
in surgery rates.
However, to ensure that the men in the urodynamic
arm are not disadvantaged by the reduction in surgery
rates, we need to ensure that the primary outcome,
symptom score, has adequate power to rule out non-
inferiority. Therefore, assuming no difference between
the groups, a trial of 310 men per arm will give 80 %
power to rule out a non-inferiority margin of 1 point
below the mean IPSS in the non-urodynamic arm, using
a 1-sided t test (common standard deviation [SD] of 5)
at the 5 % significance level. We have chosen 1 point on
the IPSS as it is a conservative estimate of the level at
which we would assume non-inferiority, since a change
of 2 points is associated with a change in global impres-
sion in urinary condition [44].
Loss to follow-up in our previous trial of conservative
treatment for men with urinary incontinence after pros-
tate surgery [25] was 5 to 10 % at 1 year. However, a
more conservative estimate of just over 20 % loss to
follow-up has been used in the sample size calculations.
Therefore, sample size will be 388 per arm to take into
account 20 % loss to follow-up. Our recruitment target
will be 400 per arm with the aim of achieving no less
than 388 per arm at 18 months follow-up.
Statistical analysis
Baseline characteristics will be examined at baseline to
ensure randomisation has provided the two pathways
with patients that are comparable on equal terms. Any
differences in excess of 0.5 SDs or 10 % or more will be
controlled for in sensitivity analyses to ensure that the
imbalance does not affect the overall result. If it does
then both the adjusted and unadjusted results will be
quoted in future reports and papers.
The analysis and reporting of the UPSTREAM trial
will be in accordance with Consolidated Standards of
Reporting Trials (CONSORT) [45] guidelines. All ana-
lyses will be on an intention-to-treat (ITT) basis where
men are assessed in the groups to which they were
assigned at randomisation. For all analyses carried out,
effects estimates will be presented along with confidence
intervals and p values. All outcomes will be described
and compared with the appropriate descriptive statistics
where relevant: mean and SD for continuous and count
outcomes, medians and inter-quartile range if required
for skewed data and numbers and percentages for
dichotomous and categorical outcomes (e.g, subjective
recurrence of incontinence).
Analysis of the primary outcome
The primary outcome will be the IPSS score at 18 months
post randomisation. This outcome is on a continuous
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scale and consists of 7 questions concerning urinary
symptoms with a 6- point Likert scale response from 0–5;
therefore, with a minimum score of 0 and maximum score
of 35. The difference between the scores for the two path-
ways will be evaluated using linear regression, adjusting
for centre and IPSS score at baseline. To assess non-
inferiority of IPSS the post-treatment difference at 18
months between the 2 arms will be used with a non-
inferiority margin of 1.0. Between-centre effects will be
examined and a mixed model approach with treatment
group as a fixed factor and investigational site as a random
effect will be considered.
The primary analysis will be based on the observed
data supported by a sensitivity analysis where all missing
data will be imputed at baseline using appropriate
imputation methods and a range of assumptions. A sen-
sitivity analysis will also be conducted to assess the treat-
ment effect for those who fully comply with the
intervention.
Analysis of secondary outcomes
All secondary outcomes listed in the ‘outcomes’ section
will be analysed using appropriate regression models,
adjusting for centre and the baseline measure of the out-
come (where possible). The main secondary outcome for
this trial is the uptake of surgery in each pathway; this
will be analysed using logistic regression. Other symp-
tom scores such as the ICIQ-MLUTS, which is poten-
tially more sensitive but less widely recognised, will be
evaluated in a similar way to the IPSS primary outcome;
adjusting for centre and baseline scores. Missing items
on the health-related outcome measures will be treated
as per the instructions for that particular measure and
imputed if necessary. Acute urinary retention as a pos-
sible complication will also be examined as secondary
outcome.
Planned further analyses
The effects of urodynamics may be more pronounced in
groups of patients with certain characteristics. Subgroup
analyses will, therefore, be carried out to assess the
difference in treatment effect for pre-specified factors.
These subgroup analyses will be carried out on the pri-
mary analysis (IPSS score) and main secondary outcome
(surgery rate). Formal tests of interaction between the
dichotomised variables and treatment pathway will be
carried out to test whether treatment effect differs
between the different subgroups of patients.
Of note, subgroup analysis will be carried out for men
presenting with more and less substantial storage LUTS
(urgency, increased frequency and nocturia), based on
the IPSS storage subscore and/or the ICIQ MLUTS
storage score.
Subgroup analysis will be undertaken for the differing
clinical diagnoses reached at the ‘Clinical Decision’ stage;
all of the factors below are on a Yes/No basis:
▪ Voiding dysfunction due to BOO, with or without
reduced bladder contractility
▪ Voiding dysfunction due to reduced bladder
contractility, with or without BOO
▪ Storage dysfunction (overactive bladder syndrome/
detrusor overactivity)
▪ Storage dysfunction (nocturia)
Proposed frequency of analyses
Men will be followed up at 6 months (by post), 12
months (post), and 18 months (clinic), after randomisa-
tion. Men undergoing surgery will also attend clinic for
flow rate testing 4 months after operation. They will be
asked to consent to longer term follow-up although this
is not funded. The main analysis will be performed when
all 18-month follow-ups have been completed. An inde-
pendent Data Monitoring Committee will review confi-
dential interim analyses of accumulating data at its
discretion.
Economic evaluation
The trial will include a formal economic evaluation com-
paring the costs and cost-effectiveness of the interven-
tions from the perspectives of the NHS, personal social
services and patients. The cost of the interventions and
the use of primary and secondary NHS services by the
men, personal and social service costs, costs to the men
arising from their treatment (e.g. over-the-counter medi-
cation) will be estimated through the collection of re-
source use data as outlined earlier and the valuation of
these data.
NHS tariffs will be used to quantify the resource use
information contained in the CRFs. All other resource
use will be valued using routine sources and information
from the patients themselves.
Differences in costs between the arms from each of
the three perspectives will be evaluated using regression
techniques adjusting for pre-specified baseline character-
istics, randomisation variables and a centre effect. The
same model specification will be used to evaluate the
differences in QALYs.
For each of the three perspectives the difference in
costs and in effectiveness in terms of surgery rates and
IPSS scores will be examined. If neither arm is domin-
ant: i.e. both cheaper and more effective, then incremen-
tal cost-effectiveness ratios will be calculated in relation
to surgery rates and IPSS scores. The differences in costs
and QALYs will be examined using the net benefit
framework over a range of values for the QALY. This
will facilitate the use of regression modelling to adjust
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for pre-specified baseline characteristics, randomisation
variables and centre effects.
Uncertainty for all these analyses will be addressed
using cost-effectiveness acceptability curves and sensitiv-
ity analyses. One aspect of uncertainty is likely to be that
of missing data. In order to address this, a pre-specified
analysis plan will be created in which the plausible as-
sumptions about missing data will be created. These as-
sumptions will then be tested within the sensitivity
analyses.
Internal feasibility phase and recruitment rates
An internal feasibility phase, intended to verify that
recruitment is possible, was first conducted in 4 centres
between months 7 and 9 (October–December 2014).
Delays in centres being ready for the trial and additional
work to improve recruitment amongst centres that were
ready meant this initial verification window was too
narrow. It was estimated that the equivalent of 12 re-
cruitment months (4 centres × 3 recruiting months each)
should yield 48 participants out of the overall accrual
target of 800; however, a more realistic assessment of
actual recruitment time meant a revised target of 17
patients, of which we recruited 13. The initial cumula-
tive accrual prediction was based on a relatively simple
linear trend assumption without incorporating differen-
tial recruitment over time by centres or different recruit-
ment rates within centres. Therefore, at the request of
the TSC, we revised the accrual projections based on a
more realistic assumption conditioned both on differen-
tial recruitment by centres over time and recruitment
capacity.
Subsequently, a further internal feasibility phase was
conducted between February and April 2015 with a
revised target of 42 participants from 4 centres, with
additional reporting to the TSC upon conclusion to gain
a realistic assessment of recruitment. Between 1 February
and 30 April the 4 centres recruited 58 participants,
exceeding the agreed target by 16.
Strategic findings from the second feasibility phase,
and implications for the trial overall, are outlined in the
discussion section of this paper (pages 23–24).
Patient panel – contribution of patient and public
involvement (PPI)
An expert panel (patient panel (PP)) of service users will
be invited to advise as we proceed through the prepar-
ation for, and the main recruitment period of, the study.
The PP will be invited to meet with the CI and/Project
Management Group (PMG) on a monthly basis in the
setting-up phase and at the conclusion of the study, and
quarterly at other times (or more often if needed). Their
guidance during the preparation of the patient consent
documentation, including information, will be vital for
the success of the consent and randomisation processes.
They will also help ensure appropriate approaches to the
delivery of the diagnostic/treatment pathway, especially
the approach to the doctor/patient decision step. They
will review communications in respect of clarity and
avoidance of potential ambiguity. We will also seek
advice from the PP on the reporting and dissemination
of findings amongst relevant patient groups, such as the
Bladder and Bowel Foundation.
Study coordination in Bristol (BRTC)
The Study Office will be based in the BRTC within the
School of Social and Community Medicine at the Univer-
sity of Bristol, and will provide day-to-day support for the
clinical centres. The Trial Manager based at the BRTC will
take responsibility for the day-to-day supervision of study
activities. The Study Administrator will provide clerical
support to the trial, including organising all aspects of the
postal questionnaires (mailing, tracking, and entering
returned data). As per BRTC’s business and costing model,
the Senior IT Manager will oversee all IT aspects of the
study, while the Senior Trials Manager will provide men-
toring and guidance to the Trial Manager and advice to
the team on generic coordination issues. The BRTC Qual-
ity Assurance Manager will oversee and demonstrate that
BRTC’s standard operating procedures for trials have been
followed and properly documented, including observance
of GCP throughout.
The UPSTREAM Study Office Team will meet for-
mally at least monthly during the course of the study to
ensure smooth running and trouble-shooting.
Project Management Group (PMG)
The study will be supervised by a PMG. The chair of this
group will be the CI and will consist of grant holders,
representatives from the Study Office and a representa-
tive from the PP. The PMG will meet monthly for the
first 6 months from study start and quarterly thereafter.
In addition, the PMG will also meet at the Trial Steering
Committee meetings.
Trial Steering Committee (TSC)
The role of the TSC is to monitor and supervise the pro-
gress of the trial. The TSC will consist of a chair and at
least two other independent members, and also the Trial
Manager and the CI. The PP of service users and the
HTA will be invited to nominate a representative to sit
on the TSC. Other non-voting members will include the
grant holders. Observers may also attend, as may other
members of the PMG or members of other professional
bodies at the invitation of the Chair.
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Data Monitoring Committee (DMC)
The DMC will also have an independent chair and at least
two other independent members, and will monitor accu-
mulating trial data during the course of the trial and make
recommendations to the TSC as to whether there are any
ethical or safety issues that may necessitate a modification
to the protocol or closure of the trial. We propose using
the DAMOCLES charter for independent DMCs (IDMCs)
as our reference point, which will be agreed in advance by
the TSC. It is anticipated that both the TSC and the DMC
would meet twice a year, once face-to-face and once via
teleconferencing. The CI, all PIs, study coordinators,
research nurses, and BRTC personnel will have under-
taken the mandatory GCP training.
Regulatory issues
Ethics approval
The CI obtained approval from the South Central –
Oxford B Research Ethics Committee (14/SC/0237). The
study must be submitted for Site Specific Assessment
(SSA) at each participating NHS Trust. The CI will
require a copy of the Trust Research and Development
(R&D) approval letter before accepting participants into
the study from that Trust (see Additional file 1 for a
complete listing of supporting Trusts). The study will be
conducted in accordance with the recommendations for
physicians involved in research on human subjects
adopted by the 18th World Medical Assembly, Helsinki
1964 and later revisions.
Sponsor
NBT will act as the Sponsor for this trial. Delegated re-
sponsibilities will be assigned to the NHS trusts taking
part in this trial.
Funding
The National Institute for Health and Research, HTA
programme are funding this study (project number
12/140/01).
Publication policy
The main forms of dissemination will be through the aca-
demic press, HTA monograph, guidelines and workshops
for clinical staff and by lay summaries on websites and
other more accessible forms for patients. All participants
will be offered a lay summary of the main findings of the
study. This will be adapted for dissemination through pub-
lic channels. Dissemination to clinicians will be through
papers in major urology journals and conferences (e.g. the
European Association of Urology), workshops and presen-
tations to national meetings: e.g. the British Association of
Urological Surgeons (BAUS), which is the specialist body
with the responsibility for guiding clinical practice, policy
matters, research priorities, governance and training in
matters related to male LUTS.
Sub-studies will also be conducted on the trial results,
written up and submitted for publication in peer-reviewed
journals.
The success of the study depends entirely on the
wholehearted collaboration of a large number of men
undergoing investigation for BPO surgery, as well as
their nurses and doctors. For this reason, chief credit for
the study will be given, not to the committees or central
organisers, but to all those who have collaborated in the
study. The results of the study will be reported first to
study collaborators. The main report will be drafted by the
PMG and circulated to all clinical collaborators for
comment. The final version will be agreed by the Steering
Committee before submission to the funders (National
Institute for Health Research (NIHR) HTA) and subse-
quent publication in a peer-reviewed journal, on behalf of
all the UPSTREAM collaborators.
To safeguard the integrity of the main trial, reports of
explanatory or satellite studies will not be submitted for
publication without prior agreement from the PMG.
We intend to maintain interest in the study by publi-
cation of UPSTREAM newsletters at intervals for partic-
ipants, staff and collaborators. Once the main report has
been published, a lay summary of the findings will be
sent in a final UPSTREAM newsletter to all involved in
the trial.
Discussion
The aim of this trial is to establish whether a care pathway
not including invasive urodynamics is no worse than one
in which it is included, in men who are considering fur-
ther treatment where surgery might be an option for
BOO. If successful, trial results could rationalise the diag-
nostic process and ensure its acceptability to patients and
advocate whether urodynamics should be recommended
or not in the future in relation to BOO; a conclusion the
NICE Guideline Development Group indicated was per-
tinent and timely.
Here, we briefly discuss some of the key challenges we
encountered during the first year of this trial, including
strategic findings from our internal feasibility assess-
ments, to provide valuable insight for research groups
conducting future similar trials.
Patient diagnostic care pathways
The second feasibility phase in particular, clearly showed
that hospitals of any type (teaching or district general)
receive sufficient inward referrals to expect delivery of
projected recruitment. However, what came to light is that
care pathways vary between each of the participating
hospitals; more so than originally anticipated. All hospitals
are structured differently and needed diverse approaches
Bailey et al. Trials  (2015) 16:567 Page 17 of 20
in terms of implementing successful identification of
patients and recruitment strategies. Finding out where
inward referrals to the urology department are triaged has
proved helpful for screening patients, as is finding where
medical notes go to after general clinics; this helps to
avoid missing potentially eligible patients.
Involvement of urologists as well as research nurses
Recruitment rates were enhanced greatly by including
urologists (local PIs and research fellows) in the identifica-
tion of patients rather than relying solely on research
nurses. We observed that the more engaged the PI was
with the trial, the smoother the initial recruitment phase.
This included the PI helping the research nurses the first
time they screen notes, regularly screening themselves
and generally encouraging the other consultants and
nurses and also involving the surrounding clinical care
team. Once patients are identified, the large majority of
men agree to participate, as the randomisation is between
two standard NHS diagnostic pathways, at the end of
which the patient chooses his treatment.
Importance of site initiation visits and ongoing
communication
We found that face-to-face site initiation visits, and follow-
up visits, were crucial to getting recruitment started in each
centre promptly and successfully. Many of the hospital
research teams work on various studies simultaneously, so
receiving direct training and encouragement helped to get
them to keep pushing for UPSTREAM recruitment. Having
a urology-trained lead research nurse dedicated solely to
UPSTREAM has been invaluable; besides assisting with on-
going communication and the monitoring of research
centres, the dedicated lead research nurse provides a direct
point of contact for nurses especially, to offer trouble-
shooting, general support and encouragement.
Furthermore, sending out a monthly newsletter com-
paring sites’ recruitment figures and indicating monthly
recruitment targets has also proved to be a useful tool to
keep sites’ focus on recruitment. This created a positive
element of competition amongst centres. Useful ‘hints
and tips’ documents on recruitment strategies, and other
relevant training materials, have also been well received.
Using multiple methods of communication (such as
newsletters, emails, trial-specific website [46], Twitter
and telephone calls) has proved essential to cater for a
wide variety of preferences.
Regular monitoring
Finally, it has been fundamental to the trial to ensure
consistent monitoring of recruitment progress, contin-
ued understanding of the trial, and all operating proce-
dures. Problems have been dealt with swiftly as a result
and suitable modifications implemented.
Trial status
Recruitment began in October 2014.
Additional file
Additional file 1: Participating hospitals and supporting NHS Trusts
that provided local research and development (R&D) approval.
(DOCX 15 kb)
Abbreviations
AE: adverse event; AIS: Assessment Information Sheet; AUA: American
Urological Association; BAUS: British Association of Urological Surgeons;
BOO: bladder outlet obstruction; BPO: benign prostatic obstruction;
BRTC: Bristol Randomised Trials Collaboration; CI: Chief Investigator;
CISC: clean intermittent self-catheterisation; CG: clinical guideline;
CONSORT: Consolidated Standards of Reporting Trials; CRF: case report forms;
DMC: Data Monitoring Committee; EQ-5D-5 L: EuroQol Group’s 5 dimension
health status questionnaire; GCP: Good Clinical Practice; GP: general
practitioner; HES: Hospital Episodes Statistics; HRQOL: health-related quality
of life; HTA: Health Technology Assessment; ICIQ-DUA: International
Consultation on Incontinence Questionnaire – Detrusor Underactivity;
ICIQ-MLUTS: International Consultation on Incontinence Questionnaire –
Male Lower Urinary Tract Symptoms; ICIQ-MLUTSsex: International
Consultation on Incontinence Questionnaire – sexual function associated
with Male Lower Urinary Tract Symptoms; ICIQ-UDS-S: ICIQ urodynamics
satisfaction; IDMC: independent data monitoring committee; IPSS: International
Prostate Symptom Score; ISRCTN: International Standard Randomised
Controlled Trial Number; ITT: intention-to-treat; IVR: interactive voice response;
LUTS: lower urinary tract symptoms; NBT: North Bristol NHS Trust; NHS: National
Health Service; NICE: National Institute for Health and Care Excellence;
NIHR: National Institute for Health Research; OAB: overactive bladder syndrome;
PI: Principal Investigator; PIS: Patient Information Sheet; PMG: Project
Management Group; PP: patient panel; PPI: patient and public involvement;
PSA: prostate specific antigen; PVR: post-void residual; QALY: quality-adjusted
life years; Qmax: maximum urinary flow rate; R&D: Research and Development;
RCT: randomised controlled trial; RUL: Resource Use Log; SD: standard deviation;
SAE: serious adverse event; SSA: Site Specific Assessment; TSC: Trial Steering
Committee; TURP: transurethral resection of prostate; UK: United Kingdom;
UDS: urodynamic studies; VV: voided volume.
Competing interests
None of the authors have any competing interests in the manuscript.
Authors’ contributions
MJD is Chief Investigator of UPSTREAM; he conceived the study, participated
in its design and coordination, and helped to draft the manuscript. PA, PSB,
CC, CG, JH, JAL, JM, SN, RP and GT also assisted with the study design. ALB
developed the trial procedures, protocol and manuscript and manages the
coordination of the study. KB developed data collection procedures and the
protocol manuscript. PSB and GJY developed the statistics and data analysis.
JH developed the qualitative elements of the study. SN developed the
health economics elements of the study. AJL further contributed to the
overall coordination of the study. All authors read and approved the final
manuscript.
Acknowledgments
This project was funded by the National Institute for Health Research HTA
programme (project number 12/140/01).
This study was designed and delivered in collaboration with the Bristol
Randomised Trials Collaboration (BRTC), a UKCRC Registered Clinical Trials
Unit in receipt of National Institute for Health Research CTU support funding.
Department of Health disclaimer
The views and opinions expressed therein are those of the authors and do
not necessarily reflect those of the HTA programme, NIHR, NHS or the
Department of Health.
Bailey et al. Trials  (2015) 16:567 Page 18 of 20
Author details
1School of Social and Community Medicine, University of Bristol, Canynge
Hall, 39 Whatley Road, Bristol BS8 2PS, UK. 2Bristol Randomised Trials
Collaboration (BRTC), University of Bristol, Canynge Hall, 39 Whatley Road,
Bristol BS8 2PS, UK. 3North Bristol NHS Trust, Bristol Urological Institute, Level
3, Learning and Research Building, Southmead Hospital, Bristol BS10 5N, UK.
4Sheffield Teaching Hospitals NHS Trust, Room H26, H-Floor, Royal
Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK. 5Health Services
Research Unit, University of Aberdeen, 3rd Floor, Health Sciences Building,
Foresterhill, Aberdeen AB25 2ZD, Scotland. 6Exeter Surgical Health Services
Research Unit – Urology, Royal Devon and Exeter Hospital, Barrack Road,
Exeter, Devon EX2 5DW, UK. 7Institute of Cellular Medicine, University of
Newcastle, 3rd Floor, William Leech Building, Newcastle upon Tyne NE2 4HH,
UK. 8University of Plymouth, Plymouth, Devon PL4 8AA, UK. 9School of
Clinical Sciences, University of Bristol, 69 St Michael’s Hill, BS2 8DZ Bristol, UK.
10Bristol Randomised Trials Collaboration, University of Bristol, St. Michael’s
Hospital, Level D, Southwell Street, Bristol, UK.
Received: 8 September 2015 Accepted: 26 November 2015
References
1. Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling JE, Lieber MM. Natural
history of prostatism: longitudinal changes in voiding symptoms in
community dwelling men. J Urol. 1996;155(2):595-600.
2. Jones C, Hill J, Chapple C. Management of lower urinary tract symptoms in
men: summary of NICE guidance. BMJ. 2010;340:c2354.
3. Abrams PH, Griffiths DJ. The assessment of prostatic obstruction from
urodynamic measurements and from residual urine. Br J Urol. 1979;51(2):129–34.
4. Abrams P. Bladder outlet obstruction index, bladder contractility index and
bladder voiding efficiency: three simple indices to define bladder voiding
function. BJU Int. 1999;84(1):14–5.
5. Griffiths CJ, Harding C, Blake C, McIntosh S, Drinnan MJ, Robson WA, et al. A
nomogram to classify men with lower urinary tract symptoms using urine
flow and noninvasive measurement of bladder pressure. J Urol. 2005;174(4
Pt 1):1323-6.
6. Harding CK, Robson W, Drinnan MJ, Griffiths CJ, Ramsden PD, Pickard RS.
An automated penile compression release maneuver as a noninvasive test
for diagnosis of bladder outlet obstruction. J Urol. 2004;172(6 Pt 1):2312-5.
7. Aagaard M, Klarskov N, Sonksen J, Bagi P, Colstrup H, Lose G. Urethral
pressure reflectometry; a novel technique for simultaneous recording of
pressure and cross-sectional area: a study of feasibility in the prostatic
urethra. BJU Int. 2012;110(8):1178-83.
8. Huang T, Qi J, Yu YJ, Xu D, Jiao Y, Kang J, et al. Predictive value of resistive
index, detrusor wall thickness and ultrasound estimated bladder weight
regarding the outcome after transurethral prostatectomy for patients with
lower urinary tract symptoms suggestive of benign prostatic obstruction. Int
J Urol.2012;19(4):343-50.
9. Park HK, Paick SH, Lho YS, Jun KK, Kim HG. Effect of the ratio of resected
tissue in comparison with the prostate transitional zone volume on voiding
function improvement after transurethral resection of prostate.Urology.
2012;79(1):202-6.
10. Shinbo H, Kurita Y. Application of ultrasonography and the resistive index
for evaluating bladder outlet obstruction in patients with benign prostatic
hyperplasia. Curr Urol Rep. 2011;12(4):255–60.
11. Ku JH, Ko DW, Cho JY, Oh SJ. Correlation between prostatic urethral angle
and bladder outletobstruction index in patients with lower urinary tract
symptoms. Urology. 2010;75(6):1467-71.
12. Parsons BA, Bright E, Shaban AM, Whitehouse A, Drake MJ. The role of
invasive and non-invasiveurodynamics in male voiding lower urinary tract
symptoms. World J Urol. 2009;2:191-7.
13. National Clinical Guideline Centre (UK). The Management of Lower Urinary
Tract Symptoms in Men [Internet]. London: Royal College of Physicians (UK);
2010. (NICE Clinical Guidelines, No. 97.) Available from: http://www.ncbi.nlm.
nih.gov/books/NBK65073/
14. Lepor H. Pathophysiology, epidemiology, and natural history of benign
prostatic hyperplasia. Rev Urol. 2004;6 Suppl 9:S3–10.
15. Girman CJ, Jacobsen SJ, Tsukamoto T, Richard F, Garraway WM, Sagnier PP,
et al. Health-related quality of life associated with lower urinary tract
symptoms in four countries. Urology. 1998;51(3):428-36.
16. Mamoulakis C, Ubbink DT, de la Rosette JJ. Bipolar versus monopolar
transurethral resection of the prostate: a systematic review and meta-
analysis of randomized controlled trials. Eur Urol. 2009;56(5):798–809.
17. Clement KD, Burden H, Warren K, Lapitan MC, Omar MI, Drake MJ. Invasive
urodynamic studies for the management of lower urinary tract symptoms (LUTS)
in men with voiding dysfunction. Cochrane Database Syst Rev. 2015;4:CD011179.
18. Oelke M, Burger M, Castro-Diaz D, Chartier-Kastler E, Jimenez Cidre MA,
McNicholas T, et al. Diagnosis and medical treatment of lower urinary tract
symptoms in adult men: applying specialist guidelines in clinical practice.
BJU Int. 2012;110(5):710-8.
19. Kristjansson B. A randomised evaluation of routine urodynamics in patients
with LUTS [abstract]. ScandinavianScand J Urol Nephrol Suppl 1999;33(Suppl
200):9.
20. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et
al. Update on AUAguideline on the management of benign prostatic
hyperplasia. J Urol. 2011;185(5):1793-803.
21. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral
resection of the prostate (TURP)–incidence, management, and prevention.
Eur Urol. 2006;50(5):969-80.
22. Schafer W, Abrams P, Liao L, Mattiasson A, Pesce F, Spangberg A, et al.
Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-
flow studies. Neurourol Urodyn. 2002;21(3):261-74.
23. Barry MJ, Fowler FJ Jr., O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust
WK, et al. The AmericanUrological Association symptom index for benign
prostatic hyperplasia. The Measurement Committee of theAmerican
Urological Association. J Urol. 1992;148(5):1549-57.
24. Abrams P, Avery K, Gardener N, Donovan J. The International Consultation
on Incontinence Modular Questionnaire: http://www.iciq.net. J Urol. 2006;
175(3 Pt 1):1063-6.
25. Glazener C, Boachie C, Buckley B, Cochran C, Dorey G, Grant A, et al.
Conservative treatment for urinary incontinence in Men After Prostate
Surgery (MAPS): two parallel randomised controlled trials. Health Technol
Assess. 2011;15(24):1-290, iii-iv.
26. Edwards PJ, Roberts I, Clarke MJ, Diguiseppi C, Wentz R, Kwan I, et al.
Methods to increase response to postal and electronic questionnaires.
Cochrane Database Syst Rev. 2009(3):MR000008.
27. Robinson KA, Dennison CR, Wayman DM, Pronovost PJ, Needham DM.
Systematic review identifies number of strategies important for retaining study
participants. J Clin Epidemiol. 2007;60(8):757-65.
28. Dindo D, Demartines N, Clavien PA. Classification of surgical complications:
a new proposal with evaluation in a cohort of 6336 patients and results of a
survey. Ann Surg. 2004;240(2):205-13.
29. Malterud K. The art and science of clinical knowledge: evidence beyond
measures and numbers. Lancet. 2001;358(9279):397–400.
30. Britten N. Qualitative interviews in medical research. BMJ. 1995;311(6999):251–3.
31. Glover L, Gannon K, McLoughlin J, Emberton M. Men’s experiences of
having lower urinary tract symptoms: factors relating to bother. BJU Int.
2004;94(4):563-7.
32. Gannon K, Glover L, O'Neill M, Emberton M. Men and chronic illness: a
qualitative study of LUTS. J Health Psychol. 2004;9(3):411-20.
33. Wareing M. Lower urinary tract symptoms: a hermeneutic phenomenological
study into men’s lived experience. J Clin Nurs. 2005;14(2):239-46.
34. Welsh L, Botelho E, Tennstedt S. Race and ethnic differences in health
beliefs about lower urinary tract symptoms. Nursing Research. 2011;60(3):
165–72.
35. Shaw C, Tansey R, Jackson C, Hyde C, Allan R. Barriers to help seeking in
people with urinary symptoms. Fam Pract. 2001;18(1):48-52.
36. Coyne KS, Sexton CC, Kopp Z, Chapple CR, Kaplan SA, Aiyer LP, et al.
Assessing patients’ descriptions of Lower Urinary Tract Symptoms (LUTS)
and perspectives on treatment outcomes: results of qualitative research. Int
J Clin Pract. 2010;64(9):1260-78.
37. Weaver T, Renton A, Tyrer P, Ritchie J. Combining qualitative studies with
randomised controlled trials is often useful. BMJ. 1996;313(7057):629.
38. Dicicco-Bloom B, Crabtree BF. The qualitative research interview. Medical
education. 2006;40(4):314–21.
39. Sandelowski M. Sample size in qualitative research. Research in nursing
& health. 1995;18(2):179–83.
40. Braun V, Clarke V. Using thematic analysis in psychology. Qualitative
Research in Psychology. 2006;3(2):77–101.
41. Boyatzis R. Transforming qualitative information: thematic analysis and code
development. London: Sage; 1998.
Bailey et al. Trials  (2015) 16:567 Page 19 of 20
42. Glaser BG, Strauss AL. The discovery of grounded theory. Chicago: Aldine; 1967.
43. Charmay K. Constructing grounded theory: a practical guide through
qualitative analysis. London: Sage; 2006.
44. Barry MJ, Cantor A, Roehrborn CG. Relationships among participant
international prostate symptom score, benign prostatic hyperplasia impact
index changes and global ratings of change in a trial of phytotherapy in
men with lower urinary tract symptoms. J Urol. 2013;189(3):987–92.
45. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, et al.
Improving the reporting of pragmatic trials: an extension of the CONSORT
statement. BMJ. 2008;337:a2390.
46. The UPSTREAM Trial University of Bristol [cited 2015 02 September].
Available from:http://www.bristol.ac.uk/social-community-medicine/people/
project/2147.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Bailey et al. Trials  (2015) 16:567 Page 20 of 20
